antibody

Fibroblast Growth Factor Receptor, phosphorylated, Tyr653/654 (FGFR)

MBS610124

0.1 mL

595 USD

polyclonal

rabbit

nonconjugated

Antibody

Fibroblast Growth Factor Receptor, phosphorylated, Tyr653/654 (FGFR)

[Fibroblast Growth Factor Receptor, Tyr653/654]

[Anti -Fibroblast Growth Factor Receptor, phosphorylated, Tyr653/654 (FGFR)]

[fibroblast growth factor receptor; Fibroblast growth factor receptor 3; fibroblast growth factor receptor 3; FGFR-3; OTTHUMP00000149958; OTTHUMP00000149959; OTTHUMP00000217007; tyrosine kinase JTK4; hydroxyaryl-protein kinase; fibroblast growth factor receptor 3]

[FGFR3; ACH; CEK2; JTK4; CD333; HSFGFR3EX]

FGFR3_HUMAN

Polyclonal

IgG

Rabbit

Human

Recognizes transfected levels of human Tyr653/654 phosphorylated FGF receptors. Crossreacts with activated PDGF receptor and insulin/IGF-I receptors. Species Sequence Homology: mouse and rat.

Purified by protein A and peptide affinity chromatography.

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol.

May be stored at 4 degree C for short-term only. For long-term storage, store at -20 degree C. Aliquots are stable for 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Western Blot (WB)

Suitable for use in Western Blot. Dilution: Western Blot: 1:1000. Incubate membrane with diluted antibody in 5% BSA, 1 x TBS, 0.1% Tween-20 at 4 degree C with gentle shaking , overnight. Optimal dilutions to be determined by the researcher.

Western Blot (WB)

Western Blot (WB)

Immunogen: Synthetic peptide (KLH coupled) corresponding to residues surrounding Tyr653/654 of human FGFR-1 (the corresponding sequences are the same in FGFR-2, -3 and -4).

Antibodies; Abs to Receptors

Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through the cellular surface tyrosine kinase receptors. There are four members of the FGF receptor family: FGFR-1 (flg), FGFR-2 (bek, KGFR), FGFR-3 and FGFR-4. Each receptor contains an extracellular ligand binding domain, a transmembrane region and a cytoplasmic kinase domain. Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues. Seven tyrosine residues in the cytoplasmic tail of FGFR-1 can be phosphorylated: Tyr463, Tyr583, Tyr585, Tyr653, Tyr654, Tyr730 and Tyr766. Tyrosines 653 and 654 are important for catalytic activity of the activated FGFR and are essential for signaling. The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCgamma.

182569

P22607

120kD, 145kD

Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Downstream Signaling Of Activated FGFR Pathway (160957); Endochondral Ossification Pathway (198812); Endocytosis Pathway (102279); Endocytosis Pathway (102181); FGFR Ligand Binding And Activation Pathway (106344); FGFR3 Ligand Binding And Activation Pathway (106352); FGFR3b Ligand Binding And Activation Pathway (106353); FGFR3c Ligand Binding And Activation Pathway (106354)

This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. Three alternatively spliced transcript variants that encode different protein isoforms have been described. [provided by RefSeq]

FGFR3: a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer. Protein type: Kinase, protein; Membrane protein, integral; Protein kinase, tyrosine (receptor); EC 2.7.10.1; Protein kinase, TK; TK group; FGFR family. Chromosomal Location of Human Ortholog: 4p16.3. Cellular Component: Golgi apparatus; internal side of plasma membrane; transport vesicle; cell surface; focal adhesion; integral to plasma membrane; perinuclear region of cytoplasm; endoplasmic reticulum; lysosome; extracellular region; plasma membrane; nucleus. Molecular Function: protein binding; fibroblast growth factor binding; fibroblast growth factor receptor activity; protein-tyrosine kinase activity; ATP binding. Biological Process: peptidyl-tyrosine phosphorylation; nerve growth factor receptor signaling pathway; somatic stem cell maintenance; protein amino acid autophosphorylation; negative regulation of transcription from RNA polymerase II promoter; bone mineralization; positive regulation of tyrosine phosphorylation of Stat3 protein; substantia nigra development; cell-cell signaling; positive regulation of MAPKKK cascade; inner ear receptor cell differentiation; positive regulation of neuron apoptosis; positive regulation of cell proliferation; forebrain development; chondrocyte differentiation; morphogenesis of an epithelium; response to axon injury; skeletal development; negative regulation of epithelial cell proliferation; endochondral ossification; epidermal growth factor receptor signaling pathway; negative regulation of developmental growth; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; myelination in the central nervous system; MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; digestive tract morphogenesis; JAK-STAT cascade; positive regulation of tyrosine phosphorylation of Stat1 protein; positive regulation of protein ubiquitination; negative regulation of smoothened signaling pathway; negative regulation of astrocyte differentiation; negative regulation of mitosis; insulin receptor signaling pathway; innate immune response; positive regulation of endothelial cell proliferation; lens morphogenesis in camera-type eye; positive regulation of cell differentiation. Disease: Bladder Cancer; Achondroplasia; Hypochondroplasia; Muenke Syndrome; Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans; Cervical Cancer; Thanatophoric Dysplasia, Type I; Crouzon Syndrome With Acanthosis Nigricans; Colorectal Cancer; Camptodactyly, Tall Stature, And Hearing Loss Syndrome; Lacrimoauriculodentodigital Syndrome; Thanatophoric Dysplasia, Type Ii; Testicular Germ Cell Tumor; Nevus, Epidermal

0.1 mL

595 USD